Brief: NGM Bio Announces Positive Preliminary Topline Liver Histology And Biomarker Data From 24-Week Phase 2 Study Of Aldafermin In Nash Patients

NGM Biopharmaceuticals

24/02/2020 13:16

Feb 24 (Reuters) - NGM Biopharmaceuticals Inc  NGM.O :
    * NGM BIO ANNOUNCES POSITIVE PRELIMINARY TOPLINE LIVER
HISTOLOGY
AND BIOMARKER DATA FROM 24-WEEK PHASE 2 STUDY (COHORT 4) OF
ALDAFERMIN IN NASH PATIENTS, INCLUDING STATISTICALLY SIGNIFICANT
ACHIEVEMENT OF COMPOSITE ENDPOINT OF BOTH FIBROSIS IMPROVEMENT
AND RESOLUTION OF NASH VERSUS PLACEBO
    * NGM BIOPHARMACEUTICALS - CLINICALLY MEANINGFUL RESPONSE
RATES OF
38% OF PATIENTS TREATED WITH ALDAFERMIN HAVING LIVER FIBROSIS
IMPROVEMENT OF ≥1 STAGE
    * NGM BIOPHARMA - 22% OF ALDAFERMIN-TREATED PATIENTS VERSUS
0%
PLACEBO ACHIEVED COMPOSITE ENDPOINT OF BOTH FIBROSIS IMPROVEMENT
& RESOLUTION OF NASH
    * NGM BIOPHARMACEUTICALS - COHORT 4 POWERED TO DEMONSTRATE
EFFECT
OF ALDAFERMIN TREATMENT VERSUS PLACEBO, WHICH ACHIEVED
STATISTICAL SIGNIFICANCE
    * NGM BIOPHARMA -STUDY ASSESSED SECONDARY ENDPOINTS OF LIVER
HISTOLOGY, BIOMARKERS OF DISEASE ACTIVITY, MANY OF WHICH
ACHIEVED STATISTICAL SIGNIFICANCE
    * NGM BIOPHARMA - PATIENTS TREATED WITH ALDAFERMIN
DEMONSTRATED
STATISTICALLY SIGNIFICANT IMPROVEMENTS IN EACH OF NAFLD ACTIVITY
SCORE COMPONENTS
    * NGM BIOPHARMACEUTICALS - STATISTICALLY SIGNIFICANT
PROPORTION IN
ALDAFERMIN TREATMENT ARM (62%) EXPERIENCED TWO-POINT IMPROVEMENT
IN TOTAL NAS
    * NGM BIOPHARMACEUTICALS - NGM PLANS TO INITIATE PHASE 2B
ALPINE 4
STUDY

Source text for Eikon:  ID:nGNX9V7yRM 
Further company coverage:  NGM.O 

 ((Reuters.Briefs@thomsonreuters.com;))